Home › NDC Lookup › RxCUI directory › RxCUI 2055650

2 ML lanadelumab-flyo 150 MG/ML Injection [Takhzyro] — RxCUI 2055650

Name: 2 ML lanadelumab-flyo 150 MG/ML Injection [Takhzyro] (RxCUI 2055650)
Creator: Brian Staiger, PharmD

RxNorm drug concept · Semantic branded drug

RxCUI 2055650 Semantic branded drug · SBD ● Current RxNorm concept 3 FDA products 3 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by Dr. Brian Staiger, PharmD

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2055650

Official name2 ML lanadelumab-flyo 150 MG/ML Injection [Takhzyro]

Concept typeSemantic branded drug (SBD)

RxNorm statusCurrent RxNorm concept

Also known as2 ML Takhzyro 150 MG/ML Injection; TAKHZYRO 300 MG in 2 ML Injection; Takhzyro 300 MG per 2 ML Injection

FDA products mapped3

Package NDCs mapped3

Reported Medicaid activity (SDUD)2,602 prescriptions · 28 state & territory Medicaid programs · latest period Q4 2025

RxNorm release07/06/2026

Snapshot dataJul 14, 2026

🕸️ Concept Web — How 2 ML lanadelumab-flyo 150 MG/ML Injection [Takhz... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.

This page's concept 2 ML lanadelumab-flyo 150 MG/ML Injection [Takhzyro] RxCUI 2055650 Semantic branded drug · SBD

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

Ingredients 2

The active substance itself — no strength, form, or brand attached yet.
- Lanadelumab 2055641 IN
- Lanadelumab-flyo 2055640 PIN
Brand names 1

The same medicine's trade names. A brand name alone says nothing about strength or form.
- Takhzyro 2055646 BN
Dose forms 9

The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
- Lanadelumab Injection 2055644 SCDF
- Lanadelumab-flyo Injection 2645702 SCDFP
- Lanadelumab Injectable Product 2055643 SCDG
- Lanadelumab-flyo Injectable Product 2661431 SCDGP
- Lanadelumab Injection [Takhzyro] 2055648 SBDF
- Lanadelumab-flyo Injection [Takhzyro] 2658334 SBDFP
- Takhzyro Injectable Product 2055649 SBDG
- Injection 1649574 DF
- +1 more in this family
Clinical & branded drugs 3

Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
- 2 ML lanadelumab-flyo 150 MG/ML Injection 2055645 SCD
- Lanadelumab-flyo 150 MG/ML 2055642 SCDC
- Lanadelumab-flyo 150 MG/ML [Takhzyro] 2055647 SBDC

Showing up to 8 concepts per family — 14 of 15 stored related concepts drawn.

These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

2 ML lanadelumab-flyo 150 MG/ML Injection SCD · 2055645
Lanadelumab-flyo 150 MG/ML SCDC · 2055642
Lanadelumab Injection SCDF · 2055644
Lanadelumab-flyo Injection SCDFP · 2645702
Lanadelumab Injectable Product SCDG · 2055643
Lanadelumab-flyo Injectable Product SCDGP · 2661431

Brand-Name Concepts

Lanadelumab-flyo 150 MG/ML [Takhzyro] SBDC · 2055647
Lanadelumab Injection [Takhzyro] SBDF · 2055648
Lanadelumab-flyo Injection [Takhzyro] SBDFP · 2658334
Takhzyro Injectable Product SBDG · 2055649
Takhzyro BN · 2055646

📦 FDA Products & Package NDCs

3 products · 3 package NDCs

3 package NDCs map to RxCUI 2055650 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.

Package NDC	Package	Brand / generic name	Labeler	Marketing start
47783-0644-01	1 VIAL, GLASS in 1 CARTON (47783-644-01) / 5 mL in 1 VIAL,...	TAKHZYRO	Takeda Pharmaceuticals America, Inc.	2018-08-24
47783-0645-01	1 SYRINGE, GLASS in 1 CARTON (47783-645-01) / 1 mL in 1 SYR...	TAKHZYRO	Takeda Pharmaceuticals America, Inc.	2023-02-03
47783-0646-01	1 SYRINGE, GLASS in 1 CARTON (47783-646-01) / 2 mL in 1 SYR...	TAKHZYRO	Takeda Pharmaceuticals America, Inc.	2022-02-08

Observed labelers: Takeda Pharmaceuticals America, Inc. (3) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🧾 Billing Codes (HCPCS)

Medical billing codes (HCPCS "J-codes") that connect to this concept's packages — used mostly when a clinic or hospital bills for a drug it administers. Each code links to its full billing page.

Code	Descriptor	Mapped packages	Sources
J0593	Inj., lanadelumab-flyo, 1 mg	2	CMS

⚠ A crosswalk is not coverage: an NDC↔HCPCS mapping does not guarantee any payer covers or pays the code. Always verify the current payer policy before billing.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7

openFDA export observedJul 14, 2026

RxNorm release07/06/2026

Methodology2026-07-full-catalog-v1

A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.

This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.